No Data
No Data
Investors in Axsome Therapeutics (NASDAQ:AXSM) Have Seen Strong Returns of 235% Over the Past Three Years
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $190
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Axsome Therapeutics (AXSM) and Greenwich LifeSciences (GLSI)
Positive Outlook on Axsome Therapeutics' AXS-12 for Narcolepsy Treatment Amid Promising Phase III Results
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5